Peter Gibbons

Rational Design, Synthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting the Respiratory Chain of Mycobacterium tuberculosis.

G. Aljayyoussi, Peter D Gibbons, G. Nixon, 2017, Journal of medicinal chemistry.

Identification of Novel Antimalarial Chemotypes via Chemoinformatic Compound Selection Methods for a High-Throughput Screening Program against the Novel Malarial Target, PfNDH2: Increasing Hit Rate via Virtual Screening Methods

Paul Stocks, Paul M. O'Neill, Neil G. Berry, 2012, Journal of medicinal chemistry.

Identification, Design and Biological Evaluation of Bisaryl Quinolones Targeting Plasmodium falciparum Type II NADH:Quinone Oxidoreductase (PfNDH2)

Peter D Gibbons, G. Nixon, R. Amewu, 2012, Journal of medicinal chemistry.

Evidence for a common non-heme chelatable-iron-dependent activation mechanism for semisynthetic and synthetic endoperoxide antimalarial drugs.

Ruth H. Hughes, R. Amewu, G. Biagini, 2007, Angewandte Chemie.

Generation of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malaria

J. Hemingway, R. Sinden, M. Delves, 2012, Proceedings of the National Academy of Sciences.

Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.

C. Davis, B. K. Park, Peter D Gibbons, 2009, Journal of medicinal chemistry.

A novel drug for uncomplicated malaria: targeted high throughput screening (HTS) against the type II NADH:ubiquinone oxidoreductase (PfNdh2) of Plasmodium falciparum

Peter D Gibbons, V. Barton, G. Nixon, 2010, Malaria Journal.